Kolis Scientific, a company developing an outpatient-based ophthalmic treatment, has emerged from stealth mode in a big way, but is still reluctant to discuss in detail its technology and focus.
Kolis, which is based in Morrisville, has landed $15.07 million in venture capital funding. News that leaked about the financing has thrust the company onto the radar screen, if you will, of potential competitors and other interested parties.
Kolis investors include Quaker BioVentures, De Novo Ventures and Spray Venture Partners.
“We’re really early,” Chief Executive Officer Tim Willis told WRAL Local Tech Wire in a brief interview. He declined to discuss any more information.
Kolis was first identified by Spray Venture Partners, a Newton, Mass.-based venture capital firm, as one of its portfolio companies. According to Spray, Kolis is developing “novel, device-based therapies to treat a common ophthalmic condition.”
Spray invests in startups, providing capital as well as management expertise for what it describes as “clinical and technical founders” of companies.
De Novo Ventures is based in Menlo Park, Calif.
Quaker BioVentures is based in Philadelphia. It is no stranger in the Triangle, having made investments in Biolex, which is based in Pittsboro, Tranzyme Pharma, which is based in Durham, and Regado Biosciences, which is based in Morrisville.